The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial
Open accessAbstract
Importance: There is limited information about the relative effectiveness of cervical cancer screening with primary human papillomavirus (HPV) testing alone compared with cytology in North American populations. Objective: To evaluate histologically confirmed cumulative incident cervical intraepithelial neoplasia (CIN) grade 3 or worse (CIN3+) detected up to and including 48 months by primary HPV testing alone (intervention) or liquid-based cytology (control). Design, Setting, and Participants: Randomized clinical trial conducted in an organized Cervical Cancer Screening Program in Canada. Participants were recruited through 224 collaborating clinicians from January 2008 to May 2012, with follow-up through December 2016. Women aged 25 to 65 years with no history of CIN2+ in the past 5 years, no history of invasive cervical cancer, or no history of hysterectomy; who have not received a Papanicolaou test within the past 12 months; and who were not receiving immunosuppressive therapy were eligible. Interventions: A total of 19 009 women were randomized to the intervention (n = 9552) and control (n = 9457) groups. Women in the intervention group received HPV testing; those whose results were negative returned at 48 months. Women in the control group received liquid-based cytology (LBC) testing; those whose results were negative returned at 24 months for LBC. Women in the control group who were negative at 24 months returned at 48 months. At 48-month exit, both groups received HPV and LBC co-testing. Main Outcomes and Measures: The primary outcome was the cumulative incidence of CIN3+ 48 months following randomization. The cumulative incidence of CIN2+ was a secondary outcome. Results: Among 19 009 women who were randomized (mean age, 45 years [10th-90th percentile, 30-59]), 16 374 (8296 [86.9%] in the intervention group and 8078 [85.4%] in the control group) completed the study. At 48 months, significantly fewer CIN3+ and CIN2+ were detected in the intervention vs control group. The CIN3+ incidence rate was 2.3/1000 (95% CI, 1.5-3.5) in the intervention group and 5.5/1000 (95% CI, 4.2-7.2) in the control group. The CIN3+ risk ratio was 0.42 (95% CI, 0.25-0.69). The CIN2+ incidence rate at 48 months was 5.0/1000 (95% CI, 3.8-6.7) in the intervention group and 10.6/1000 (95% CI, 8.7-12.9) in the control group. The CIN2+ risk ratio was 0.47 (95% CI, 0.34-0.67). Baseline HPV-negative women had a significantly lower cumulative incidence of CIN3+ at 48 months than cytology-negative women (CIN3+ incidence rate, 1.4/1000 [95% CI, 0.8-2.4]; CIN3+ risk ratio, 0.25 [95% CI, 0.13-0.48]). Conclusions and Relevance: Among women undergoing cervical cancer screening, the use of primary HPV testing compared with cytology testing resulted in a significantly lower likelihood of CIN3+ at 48 months. Further research is needed to understand long-term clinical outcomes as well as cost-effectiveness. Trial Registration: isrctn.org Identifier: ISRCTN79347302.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
The causal relation between human papillomavirus and cervical cancer
Bosch, F. X., Lorincz, A., Munoz, N., Meijer, C. J. L. M., & Shah, K. V. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.4.244 · Cited by 3,538
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B., Naud, P., De Carvalho, N. S., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17398-4 · Cited by 1,643
Self-citationA Controlled Trial of a Human Papillomavirus Type 16 Vaccine
Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., & Jansen, K. U. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020586 · Cited by 1,602
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., Wheeler, C. M., Koutsky, L. A., Malm, C., Lehtinen, M., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70101-7 · Cited by 1,579
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.10897 · Cited by 1,409
Cuzick, J., Clavel, C., Petry, K., Meijer, C. J. L. M., Hoyer, H., Ratnam, S., Szarewski, A., Birembaut, P., Kulasingam, S., Sasieni, P., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21955 · Cited by 1,141
Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer
Mayrand, M.-H., Duarte-Franco, E., Rodrigues, I., Walter, S. D., Hanley, J., Ferenczy, A., Ratnam, S., Coutlée, F., & Franco, E. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071430 · Cited by 1,100
Self-citationNanda, K., McCrory, D. C., Myers, E. R., Bastian, L. A., Hasselblad, V., Hickey, J. D., & Matchar, D. B. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-10-200005160-00009 · Cited by 1,089
Screening for cervical cancer: U.S. preventive services Task force recommendation statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-12-201206190-00424 · Cited by 1,049
Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Palma, P. D., Del Mistro, A., Ghiringhello, B., Girlando, S., Gillio-Tos, A., De Marco, L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70360-2 · Cited by 936
Bulkmans, N., Berkhof, J., Rozendaal, L., van Kemenade, F., Boeke, A., Bulk, S., Voorhorst, F., Verheijen, R., van Groningen, K., Boon, M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61450-0 · Cited by 637
Dillner, J., Rebolj, M., Birembaut, P., Petry, K.-U., Szarewski, A., Munk, C., de Sanjose, S., Naucler, P., Lloveras, B., Kjaer, S., et al. (2008) · BMJ · doi:10.1136/bmj.a1754 · Cited by 629
Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial Neoplasia
Schlecht, N. F. (2001) · JAMA · doi:10.1001/jama.286.24.3106 · Cited by 590
Schiffman, M., Herrero, R., Hildesheim, A., Sherman, M. E., Bratti, M., Wacholder, S., Alfaro, M., Hutchinson, M., Morales, J., Greenberg, M. D., et al. (2000) · JAMA · doi:10.1001/jama.283.1.87 · Cited by 540
Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer
Franco, E. L., Rohan, T. E., & Villa, L. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.6.506 · Cited by 533
Self-citationGarland, S. M., Kjaer, S. K., Muñoz, N., Block, S. L., Brown, D. R., DiNubile, M. J., Lindsay, B. R., Kuter, B. J., Perez, G., Dominiak-Felden, G., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw354 · Cited by 497
Huh, W. K., Ault, K. A., Chelmow, D., Davey, D. D., Goulart, R. A., Garcia, F. A. R., Kinney, W. K., Massad, L. S., Mayeaux, E. J., Saslow, D., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.12.022 · Cited by 489
Clavel, C., Masure, M., Bory, J.-P., Putaud, I., Mangeonjean, C., Lorenzato, M., Nazeyrollas, P., Gabriel, R., Quereux, C., & Birembaut, P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1845 · Cited by 465
Management of women who test positive for high-risk types of human papillomavirus: the HART study
(2004) · Obstetrics & Gynecology · doi:10.1097/00006250-200404000-00038 · Cited by 427
Evidence for Frequent Regression of Cervical Intraepithelial Neoplasia–Grade 2
Castle, P. E., Schiffman, M., Wheeler, C. M., & Solomon, D. (2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e31818f5008 · Cited by 384
Petry, K.-U., Menton, S., Menton, M., van Loenen-Frosch, F., de Carvalho Gomes, H., Holz, B., Schopp, B., Garbrecht-Buettner, S., Davies, P., Boehmer, G., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600918 · Cited by 300
The National Co-ordinating Network for Cervical Screening Working Group, Sasieni, P., Cuzick, J., & Lynch-Farmery, E. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.196 · Cited by 292
HPV testing in primary screening of older women
Cuzick, J., Beverley, E., Ho, L., Terry, G., Sapper, H., Mielzynska, I., Lorincz, A., Chan, W.-K., Krausz, T., & Soutter, P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690730 · Cited by 268
O’Brien, B. J., & Briggs, A. H. (2002) · Statistical Methods in Medical Research · doi:10.1191/0962280202sm304ra · Cited by 251
Human papillomavirus testing for primary screening of cervical cancer precursors.
Ratnam, S., Franco, E. L., & Ferenczy, A. S. (2000) · PubMed · Cited by 240
Self-citationRozendaal, L., Walboomers, J. M. M., van der Linden, J. C., Voorhorst, F. J., Kenemans, P., Helmerhosrt, T. J. M., van Ballegooijen, M., & Meijer, C. J. L. M. (1996) · International Journal of Cancer · Cited by 223
(2006) · The Journal of Pathology · doi:10.1002/(issn)1096-9896 · Cited by 213
Cuzick, Sasieni, Davies, Adams, Normand, Frater, van Ballegooijen, & van den Akker (1999) · Health Technology Assessment · doi:10.3310/hta3140 · Cited by 204
Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline
Jeronimo, J., Castle, P. E., Temin, S., Denny, L., Gupta, V., Kim, J. J., Luciani, S., Murokora, D., Ngoma, T., Qiao, Y., et al. (2017) · Journal of Global Oncology · doi:10.1200/jgo.2016.006577 · Cited by 200
Arbyn, M., Rebolj, M., De Kok, I. M. C. M., Fender, M., Becker, N., O’Reilly, M., & Andrae, B. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.07.016 · Cited by 167
Liquid-based cytology in cervical screening: a rapid and systematic review.
Payne, Chilcott, J. B., & McGoogan (2000) · Health Technology Assessment · doi:10.3310/hta4180 · Cited by 153
Tota, J. E., Bentley, J., Blake, J. M., Coutlée, F., Duggan, M. A., Ferenczy, A. S., Franco, E. L., Fung‐Kee‐Fung, M., Gotlieb, W. H., Mayrand, M., et al. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2016.11.029 · Cited by 150
Self-citationChapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus Tests
Franco, E. L. (2003) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003488 · Cited by 146
Self-citationHuman papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Dijkstra, M. G., van Zummeren, M., Rozendaal, L., van Kemenade, F. J., Helmerhorst, T. J. M., Snijders, P. J. F., Meijer, C. J. L. M., & Berkhof, J. H. (2016) · BMJ · doi:10.1136/bmj.i4924 · Cited by 128
Mayrand, M., Duarte‐Franco, E., Coutlée, F., Rodrigues, I., Walter, S. D., Ratnam, S., Franco, E. L., & for the CCCaST Study Group (2006) · International Journal of Cancer · doi:10.1002/ijc.21897 · Cited by 122
Self-citationKotaniemi‐Talonen, L., Nieminen, P., Anttila, A., & Hakama, M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602799 · Cited by 121
Ogilvie, G. S., Krajden, M., van Niekerk, D., Smith, L. W., Cook, D., Ceballos, K., Lee, M., Gentile, L., Gondara, L., Elwood‐Martin, R., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30454 · Cited by 101
Self-citationOgilvie, G. S., van Niekerk, D. J., Krajden, M., Martin, R. E., Ehlen, T. G., Ceballos, K. M., Peacock, S. J., Smith, L., Kan, L., Cook, D. A., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-111 · Cited by 93
Self-citationHPV Testing in Primary Cervical Screening: A Systematic Review and Meta-Analysis
Murphy, J., Kennedy, E. B., Dunn, S., McLachlin, C. M., Fung, M. F. K., Gzik, D., Shier, M., & Paszat, L. F. (2012) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)35241-0 · Cited by 85
Ogilvie, G. S., Krajden, M., van Niekerk, D. J., Martin, R. E., Ehlen, T. G., Ceballos, K. M., Smith, L., Kan, L., Cook, D. A., Peacock, S. J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.489 · Cited by 84
Self-citationBulkmans, N. W. J., Rozendaal, L., Voorhorst, F. J., Snijders, P. J. F., & Meijer, C. J. L. M. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602541 · Cited by 65
Regression and Progression Predictors of CIN2 in Women Younger Than 25 Years
Loopik, D. L., Doucette, S. P., Bekkers, R. L. M., et al. (2016) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0000000000000215 · Cited by 51
Could HPV testing become the sole primary cervical screening test?
Sasieni, P. D., & Cuzick, J. M. (2002) · Journal of Medical Screening · doi:10.1136/jms.9.2.49 · Cited by 48
Evidence-based policy recommendations on cancer screening and prevention
Franco, E. L., Duarte‐Franco, E., & Rohan, T. E. (2002) · Cancer Detection and Prevention · doi:10.1016/s0361-090x(02)00118-6 · Cited by 40
Self-citationReport of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control
Stuart, G. C. E., Taylor, G., Bancej, C. M., Beaulac, J., Colgan, T. J., Franco, E. L., Kropp, R. Y., Lotocki, R. J., Mai, V., McLachlin, C. M., et al. (2004) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30423-6 · Cited by 25
Self-citationColdman, A. J., Gondara, L., Smith, L., van Niekerk, D., Ceballos, K. M., Krajden, M., Cook, D. A., Quinlan, D. J., Lee, M. H., Stuart, G. C. E., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.368 · Cited by 15
Self-citationAgramunt, S., Checa, M. Á., González-Comadran, M., Larrazábal, F., Arbós, A., Alameda, F., Mancebo, G., & Carreras, R. (2013) · Journal of Lower Genital Tract Disease · doi:10.1097/lgt.0b013e3182838b7c · Cited by 9
Cited by
Cohen, P. A., Jhingran, A., Oaknin, A., & Denny, L. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32470-x · Cited by 2,412
Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Curry, S. J., Krist, A. H., Owens, D. K., Barry, M. J., Caughey, A. B., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., et al. (2018) · JAMA · doi:10.1001/jama.2018.10897 · Cited by 1,409
Fontham, E. T. H., Wolf, A. M. D., Church, T. R., Etzioni, R., Flowers, C. R., Herzig, A., Guerra, C. E., Oeffinger, K. C., Shih, Y. T., Walter, L. C., et al. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21628 · Cited by 968
The IARC Perspective on Cervical Cancer Screening
Bouvard, V., Wentzensen, N., Mackie, A., Berkhof, J., Brotherton, J., Giorgi-Rossi, P., Kupets, R., Smith, R., Arrossi, S., Bendahhou, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmsr2030640 · Cited by 357
Self-citationMelnikow, J., Henderson, J. T., Burda, B. U., Senger, C. A., Durbin, S., & Weyrich, M. S. (2018) · JAMA · doi:10.1001/jama.2018.10400 · Cited by 302
Metadata
- Authors
- Ogilvie, G. S., van Niekerk, D., Krajden, M., Smith, L. W., Cook, D., Gondara, L., Ceballos, K., Quinlan, D., Lee, M., Martin, R. E., Gentile, L., Peacock, S., Stuart, G. C. E., Franco, E. L., & Coldman, A. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2018-07-03
- Volume
- 320
- Issue
- 1
- Pages
- 43
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2810057587
- Cited by
- 279
- References
- 52
- FWCI
- 23.18
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.